Here are three of the latest updates on new hires and promotions from these Houston organizations. Photos courtesy

It's been a busy year so far for Houston organizations — three of which have made new appointments to their leadership.

In this round up of movers and shakers in Houston innovation, a venture capital firm names its newest principal, an astronaut gets a leadership role here at ground control, and a VR studio snags a leader to steer its growth.

Joe Acaba, chief of NASA's Astronaut Office at Johnson Space Center

Joe Acaba was promoted to a new role and will be responsible for crew assignments for future spaceflight missions. Photo via NASA

NASA tapped Joe Acaba as its chief of the Astronaut Office based in Johnson Space Center in Houston. He's served on multiple spaceflights and is a former U.S. Marine and former educator. According to NASA, he's the first person of Hispanic heritage selected to lead the office.

Acaba replaces Drew Feustel, who spent two years as deputy chief and has been acting chief of the office since NASA astronaut Reid Wiseman left the post late last year.

"Joe is an experienced space flyer and a proven leader, and he will undoubtedly inspire the next generation of NASA astronauts," says NASA Administrator Bill Nelson in a news release. " As we build on the International Space Station’s unparalleled success in low-Earth orbit with our eyes on the Moon and then Mars, Joe will play an integral role in ensuring our NASA astronauts are prepared for the challenges ahead."

Acaba, who spent a total of 306 days in space, has already supported the astronaut office in a few of roles, including director of operations in Russia and chief of the Vehicle Integration Test Office. In this new role, he will be oversee astronaut resources and operations and help develop astronaut flight crew operation concepts. Additionally, Acaba will make crew assignments for future spaceflight missions, including astronauts assigned to fly on Artemis missions.

“Our Johnson Space Center team congratulates Joe Acaba on his selection to chief of the Astronaut Office. We wish him well as he takes on this new and exciting leadership role,” says NASA Johnson Space Center Director Vanessa Wyche.

Samantha Lewis, partner at Mercury Fund

Samantha Lewis was promoted to partner at Mercury Fund. Photo courtesy of Mercury Fund

Samantha Lewis was promoted to partner from principal at Houston-based venture capital firm Mercury, per her LinkedIn. She previously was the investment director of investor network GOOSE Capital before joining the Mercury team just over two years ago.

Last year, Lewis — who also served on the board of two Houston-founded startups, Syzygy and Topl — was named a member of the Class 27 of the Kauffman Fellows Program, a group of global innovation investors.

Lewis is focused on what she calls the "power theme" at Mercury, which includes fintech, blockchain, web3, and more. She told InnovationMap on a recent episode of the Houston Innovators Podcast that these industries have been hit in particular within market uncertainty.

Bob Kleinhample, senior vice president of growth at HTX Labs

Bob Kleinhample joins HTX Labs at a time of strategic growth. Photo courtesy of HTX Labs

Virtual reality studio HTX Labs has named Bob Kleinhample as the company’s senior vice president of growth. He has more than 15 years leading business efforts in the tech space. A 20-year Army veteran, Kleinhample will oversee all aspects of HTX Labs' growth — including business development, product strategy, and marketing.

“Bob brings the right balance of market knowledge and product strategy, in combination with the commitment to bring immersive training and simulation to the warfighter, to really drive our EMPACT offering into the market,” says Scott Schneider, CEO and co-founder of HTX Labs. "We’re very excited to be adding this incredibly important role to our organization and having Bob lead these efforts as we expand the usage and adoption of EMPACT across the Department of Defense."

The appointment comes after the startup raised $3.2 million in its first outside capital round.

“Last year we secured funding from Cypress Growth Capital for the sole purpose of accelerating the growth of our EMPACT platform and our customer base, and we immediately began a search for the right person to lead these growth efforts," Schneider continues. "After performing an extensive search, we are fortunate to have connected with Bob Kleinhample who is coming on board to lead our company’s growth efforts“.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.